United Therapeutics Corporation Share-based Payment Arrangement, Exercise of Option, Tax Benefit
United Therapeutics Corporation (UTHR) reported Share-based Payment Arrangement, Exercise of Option, Tax Benefit of $21.60 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions · last filed 2023-02-22
- United Therapeutics Corporation share-based payment arrangement, exercise of option, tax benefit for fiscal 2022 was $21.60M, a 307.55% increase from fiscal 2021.
- United Therapeutics Corporation share-based payment arrangement, exercise of option, tax benefit for fiscal 2021 was $5.30M, a 1.85% decline from fiscal 2020.
- United Therapeutics Corporation share-based payment arrangement, exercise of option, tax benefit for fiscal 2020 was $5.40M, a 107.69% increase from fiscal 2019.
- United Therapeutics Corporation share-based payment arrangement, exercise of option, tax benefit for fiscal 2019 was $2.60M.
| Period end | Share-based Payment Arrangement, Exercise of Option, Tax Benefit 12 month |
|---|---|
| 2022-12-31 | $21.60M 10-K · filed 2023-02-22 |
| 2021-12-31 | $5.30M 10-K · filed 2023-02-22 |
| 2020-12-31 | $5.40M 10-K · filed 2023-02-22 |
| 2019-12-31 | $2.60M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |